Join the Contact Dermatitis group to help and get support from people like you.
Contact Dermatitis News (Page 2)
Related terms: Allergic Dermatitis, Dermatitis, Allergic, Dermatitis, Contact
FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitis
WEDNESDAY, Dec. 18, 2024 – The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older. ...
Dupilumab Efficacious for Atopic Dermatitis in Young Children
WEDNESDAY, Dec. 11, 2024 – Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published in the December issue of Advances in Therapy. ...
FDA Medwatch Alert: Do Not Purchase or Use Skin-Cap Aerosol Spray Products Because They May Be Harmful to Your Health
October 30, 2024 – FDA is warning consumers to not purchase or use Skin-Cap aerosol spray products because they may contain undisclosed steroids. This product, sold by Chemigroup France, formerly...
Long-Term Upadacitinib Use Feasible for Adolescents With Atopic Dermatitis
FRIDAY, Oct. 25, 2024 – Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective through 76 weeks, according to a study published...
Are 'Elimination Diets' Much Help Against Child Eczema?
FRIDAY, Oct. 25, 2024 – Cutting certain foods from a child’s diet isn’t likely to improve their eczema symptoms, a new study finds. Eczema, also known as atopic dermatitis, results from an ove...
Eczema Could Be Linked to Poorer Leg Artery Function
TUESDAY, Oct. 22, 2024 – The skin condition eczema appears to be linked to a serious condition that can end in leg amputation, a new study finds. People with eczema are at significantly higher risk...
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
WEDNESDAY, Sept. 18, 2024 – The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older with moderate-to-severe atopic dermatitis....
Link Between n-3 LCPUFA, Eczema Varies by Maternal COX1 Genotype
WEDNESDAY, Sept. 4, 2024 – The association of prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) with the risk for childhood atopic dermatitis (AD) varies based on the maternal ...
Dietary Vitamin E May Be Protective Against Atopic Dermatitis
FRIDAY, Aug. 30, 2024 – Dietary intake of vitamin E may potentially lower the risk for atopic dermatitis, according to a study published online Aug. 9 in Skin Research & Technology. Siqing Wang, ...
Childhood Obesity Tied to Pediatric Immune-Mediated Skin Diseases
TUESDAY, Aug. 27, 2024 – Early childhood obesity may increase the risk for pediatric immune-mediated skin diseases, according to a study published online Aug. 21 in the Journal of Investigative ...
Dupilumab Maintains Its Effectiveness Up to Five Years in Patients With Eczema
MONDAY, Aug. 12, 2024 – For patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8 percent of patients, according to a...
FDA Approves Tris Pharma's New Drug Application for Karbinal ER
MONMOUTH JUNCTION, N.J., April 3, 2013 /PRNewswire/ – Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that the U.S. Food...
Further information
Related condition support groups
Related drug support groups
prednisone, methylprednisolone, clobetasol, Dupixent, fluocinonide, dexamethasone, desonide, halobetasol, dupilumab